Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History JANX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics JANX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Janux Therapeutics Inc

JANX
Current price
22.88 USD -0.48 USD (-2.05%)
Last closed 23.60 USD
ISIN US47103J1051
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 344 460 544 USD
Yield for 12 month -47.06 %
1Y
3Y
5Y
10Y
15Y
JANX
21.11.2021 - 28.11.2021

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California. Address: 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

84.12 USD

P/E ratio

Dividend Yield

Financials JANX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures JANX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+10 588 000 USD

Last Year

+8 083 000 USD

Current Quarter

Last Quarter

Current Year

+8 528 000 USD

Last Year

+6 128 000 USD

Current Quarter

Last Quarter

EBITDA -111 536 000 USD
Operating Margin TTM -1 216.61 %
Price to Earnings
Return On Assets TTM -8.16 %
PEG Ratio
Return On Equity TTM -9.32 %
Wall Street Target Price 84.12 USD
Revenue TTM 9 336 000 USD
Book Value 17.11 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM -70 037 000 USD
Earnings per share -1.36 USD
Diluted Eps TTM -1.36 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation JANX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 37.80
Price Sales TTM 144.01
Enterprise Value EBITDA -33.80
Price Book MRQ 1.33

Technical indicators JANX

For 52 weeks

22.48 USD 71.71 USD
50 Day MA 26.77 USD
Shares Short Prior Month 11 548 285
200 Day MA 40.50 USD
Short Ratio 8.41
Shares Short 10 671 942
Short Percent 26.09 %